Amphotret (amphotericin B) 50 mg, for intravenous injection, Bharat Serums & Vaccines, India в Молдове

WDSS
Medicines
Originator medicines
Amphotret (amphotericin B) 50 mg, for intravenous injection, Bharat Serums & Vaccines, India

Delivery methods

Delivery of non-temperature-controlled medicines to Chisinau - $25.
Delivery of temperature-controlled medicines to Chisinau - $50.
Up to 5 packages can be sent per shipment. The price applies to one shipment.
Pickup from Odesa

free
Shipping within Ukraine by Nova Poshta at the carrier's rates.
Payment in UAH upon receipt of the order.

Delivery time

Originator medicines: 5-7 days
Generic medicines: 3-4 days

Payment methods

Bank transfer to the settlement account after receiving the order
Payment upon pickup in Odesa

Description

Interchangeable drugs with the same active ingredient:
Ampholip
Amphotret
Fungizome
Fungizone
composition
active ingredient: 1 bottle contains 50 mg of amphotericin B;
excipients: sodium deoxycholate, diluted phosphoric acid, sodium hydroxide.
Dosage form
Lyophilisate for the preparation of solution for infusion.
Pharmacological group
Antifungal agents for systemic use. Antibiotics. ATC code J02A A01.
indications
Systemic mycoses candidomycosis, aspergillosis, histoplasmosis, cryptococcosis, coccidioidosis,
blastomycosis, mucormycosis.
Treatment of potentially life-threatening fungal infections caused by susceptible species.
Treatment of American leishmaniasis of the skin and mucous membranes.
Treatment of patients with persistent fever caused by impaired immunity, when previous antibacterial therapy did not give the desired result.
Contraindications
The drug should not be used to treat non-invasive fungal infections.
The drug is contraindicated in patients with severe forms of pathology of the kidneys, liver, hematopoietic system, patients with diabetes mellitus, with hypersensitivity to amphotericin B or to any other component included in the dosage form, except in cases where the disease, in the opinion of the doctor, threatens the patient’s life, and the pathogen is sensitive only to amphotericin
Dosage and administration
The drug should be used by slow drip infusion. Intravenous infusion of the drug should be carried out over 2-6 hours, following the usual measures for intravenous infusions. The recommended concentration for intravenous infusion is 0,1 mg/ml (1 mg/10 ml). Since the drug is tolerated differently by patients, the dose should be selected and adjusted individually, taking into account the localization and intensity of the infection, which is the etiological factor.
Treatment usually begins with a daily dose of 0,25 mg/kg body weight, and this dose is administered over 2-6 hours. The first test dose (1 mg in 20 ml of 5% glucose solution), administered intravenously over 20-30 minutes, can be a guideline, although this is not an absolutely reliable method for assessing individual tolerability of the drug. The patient’s body temperature, pulse, respiratory rate and blood pressure should be measured at intervals
30 minutes for 2-4 hours. A patient with a severe and rapidly progressing fungal infection, in the absence of disorders of the cardiovascular and respiratory systems, and if he has tolerated a test dose without a severe reaction, the drug can be administered intravenously at a dose of 0,3 mg/kg over 2-6 hours. A lower dose, for example 5-10 mg, is recommended for patients with impaired cardiovascular or respiratory system function with a certain response to the test dose. The dose can be gradually increased from 5-10 mg per day to the average daily dose -
0,5-1 mg / kg. At present, insufficient data have been accumulated based on controlled clinical studies to determine the dose and duration of treatment for patients with various forms of mycoses (for example, mucormycosis). The optimal dose remains unknown, and the selection of an effective and at the same time sufficiently safe dose is largely carried out empirically. The recommended daily dose may be 1 mg/kg per day or 1,5 mg/kg every other day in the case of severe infections caused by fairly resistant pathogens.
ATTENTION! Under any circumstances, the total daily dose should not exceed 1,5 mg/kg.An overdose of the drug can lead to arrest of cardiopulmonary activity (see Section “Overdose”).
For children, the drug is prescribed intravenously from 5 months to 18 years. The initial daily dose is 0,25 mg/kg body weight in a 5% glucose solution when administered over 6:00. In the absence of adverse reactions, the dose can be gradually increased (usually by 0,125-0,25 mg/kg every day or every other day) to a maximum dose of 1 mg/kg body weight.
Candidomycosis . For disseminated infections caused by Candida , the usual dose, which ranges from 0,4 to 0,6 mg/kg/day, is used for 4 weeks or more. Depending on the severity of the infection, doses up to 1 mg/kg/day can be used. Treatment continues until signs of clear clinical improvement appear; adult patients may require general cumulative doses of the drug of 2-4 g. Smaller doses (0,3 mg / kg / day) may be needed in special cases, for example, with esophagitis caused by Candida resistant to local treatment, or when the drug is used in combination with other antifungal drugs.
Cryptococcosis . For the treatment of patients without immune system disorders, doses as low as 0,3 mg/kg/day may typically be needed for approximately 4-6 weeks or until weekly cultures are negative for a month. For patients with immunosuppression and meningitis, the drug can be prescribed in combination with other antifungal agents for 6 weeks.
Patients with cryptococcal meningitis who have acquired immunodeficiency syndrome (AIDS) may need higher doses (0,7-0,8 mg / kg / day), and courses of treatment can last up to
12 weeks. In relation to AIDS patients with negative culture results after a standard course of treatment, the use of a long-term maintenance dose, for example a dose of 1 mg / kg per week, should be considered.
Coccidioidosis . If necessary, treatment of primary coccidioidosis, the drug in doses of
1 mg / kg/day to a maximum of 1,5 mg/kg/day is prescribed in cumulative doses - from
0,5 to 2,5 g for adults, depending on the severity of the infection and its location. For coccidial meningitis, systemic (intravenous) and intrathecal administration of the drug is possible.
Blastomycosis . For severe patients with blastomycosis, it is recommended to use the drug in doses of 0,3-1 mg / kg / day in a total cumulative dose, in adults it may be from 1,5 to 2,5 g.
Histoplasmosis . For chronic pulmonary or disseminated histoplasmosis in adult patients, doses are usually recommended from approximately 0,5 to 1 mg / kg / day for a total cumulative dose of 2-2,5 g.
Aspergillosis . Aspergillosis was treated with amphotericin B intravenously for 11 months.For the treatment of severe infections, doses of 0,5-1 mg/kg/day or more are required, adults may need cumulative doses of 2-4 g (for example, for pneumonia or the presence of fungal pathogens in the blood). The duration of treatment for severe mycoses can be
6-12 weeks or more.
Rhinocerebral mucormycosis . This active disease usually develops in connection with diabetic ketoacidosis. For treatment with amphotericin to be successful, rapid restoration of the degree of compensation for diabetes mellitus is absolutely necessary. Since rhinocerebral mucormycosis usually quickly leads to death, the therapeutic approach, if necessary, should be more aggressive than for relatively mild mycoses.
Preparation of solutions.
<span style="bo

Specifications

Trade name:

Amphotret
Chemical name:

Amphotericin B
Dosage:

50 mg
Dosage form:

Ampoule

Reviews

No reviews yet